Professor, Medicine, University of Florida College of Medicine
Oncology
Dr. Nam H. Dang, MD
|
|
Give Review
Dang works in the field of Oncology. He studied medicine at Harvard Medical School. Harvard Medical School is a top medical university. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He received 1 awards: "CMS Meaningful Use Stage 1 Certification". Dr. Nam H. Dang has written publications. He has 48 publications published with PubMed. The lastest paper is: 'Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma.' He is registered with Medicare and accepts Medicare payments.
Publications
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell Lymphoma.
- Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma.
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma.
- Involved-Node Proton Therapy in Combined Modality Therapy for Hodgkin Lymphoma: Results of a Phase 2 Study.
- ALK1 as a Novel Therapeutic Target for CD30+ T-Anaplastic Large Cell Lymphoma.
- Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin...
- The role of monoclonal antibodies in the treatment of Lymphomas.
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II...
- CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in Malignant pleural mesothelioma.
- A Phase 1 Study of AME-133v (LY2469298) an Fc-Engineered Humanized Monoclonal Antibody in Fc?RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma.
- Combination Therapy for Renal Cell Cancer: What Are Possible Options?
- Consolidative Involved-Node Proton Therapy for Stage IA-IIIB Mediastinal Hodgkin Lymphoma: Preliminary Dosimetric Outcomes from a Phase II Study.
- Dipeptidyl peptidase in autoImmune pathophysiology.
- Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.
- Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells.
- CD90 and CD110 correlate with cancer stem cell potentials in human T-Acute lymphoblastic leukemia cells.
- SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.
- CD9 correlates with cancer stem cell potentials in human B-Acute lymphoblastic leukemia cells.
- Novel antibody approaches for T-cell Lymphomas.
- Bendamustine: a novel cytotoxic agent for hematologic malignancies.
- De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T-cell Lymphoma is associated with prolonged remission.
- Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.
- Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.
- The role of CD26/dipeptidyl peptidase IV in Cancer.
- Comparative study of regulatory T cell function of human CD25CD4 T cells from thymocytes, cord blood, and adult peripheral blood.
- Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell Leukemia/lymphoma.
- Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
- Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma Tumors.
- Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1.
- Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant Cancer cells.
- Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dep...
- Nedd9 protein, a Cas-L homologue, is upregulated after transient global ischemia in rats: possible involvement of Nedd9 in the differentiation of neurons after ischemia.
- High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell Lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-...
- CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells.
- CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic l...
- Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience.
- Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell Lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced i...
- Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's Lymphoma.
- Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's Lymphoma.
- CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.
- Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's Lymphoma and Hodgkin's disease.
- Denileukin diftitox as novel targeted therapy in non-Hodgkin's Lymphoma.
- Thalidomide for patients with recurrent Lymphoma.
- Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation.
- SS-A/Ro52, an autoantigen involved in CD28-mediated IL-2 production.
- Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
- New primary malignancy masquerading as metastatic proState adenocarcinoma.
Schools
Harvard Medical School
Massachusetts General Hospital
Dana Farber Canc Institute
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Harvard Medical School
Hospital
-
UF Health Shands Hospital
Drug Facts
| NPI NUMBER | 1871593913 | |
| NPPES Provider LastName | DANG | |
| NPPES Provider FirstName | NAM | |
| NPPES Provider ZIPCode | 326103003 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 70.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1871593913 |
| Last Name Of The Provider | DANG |
| First Name Of The Provider | NAM |
| View All |
Similar Doctors
|
|
Dr. Bruce K. Stechmiller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Wingard, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Coy D. Heldermon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles E. Riggs Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merry J. Markham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Priya K. Gopalan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel J. Farrugia, MD
This Doctor is OpenDoctor Recommended.
|